Standout Papers

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carci... 2020 2026 2022 2024468
  1. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020)
    Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology

Immediate Impact

8 by Nobel laureates 58 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
1 intermediate paper

Works of Dmitry Nosov being referenced

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Dmitry Nosov 892 513 516 40 1.1k
Vahur Valvere 524 390 769 27 1.3k
Mariajosé Lechuga 547 255 467 22 975
Jiří Tomášek 803 510 654 54 1.3k
Gaetano Aurilio 710 309 711 64 1.3k
Júlio Oliveira 396 269 488 40 1.0k
Daniel Swinson 758 243 547 44 1.4k
Sei Naito 774 738 389 99 1.3k
Mimma Rizzo 672 475 418 76 1.1k
Beata Korytowsky 608 367 554 77 1.0k
Alessia Mennitto 449 259 526 58 960

All Works

Loading papers...

Rankless by CCL
2026